Meng An Bought 5.8% More Shares In Consun Pharmaceutical Group
Meng An Bought 5.8% More Shares In Consun Pharmaceutical Group
Those following along with Consun Pharmaceutical Group Limited (HKG:1681) will no doubt be intrigued by the recent purchase of shares by Meng An, CEO & Executive Chairman of the company, who spent a stonking HK$5.4m on stock at an average price of HK$5.64. There's no denying a buy of that magnitude suggests conviction in a brighter future, although we do note that proportionally it only increased their holding by 5.8%.
關注康臣藥業集團有限公司(HKG:1681)的人無疑會對公司的首席執行官兼執行主席孟安最近購買股票的行爲感到好奇,他花了540萬港元以平均5.64港元的價格購買了一大筆股票。毫無疑問,這種規模的買入行爲表明對更加光明的未來的信心,儘管我們注意到,從比例上看,這僅增加了他們持有的股份5.8%。
The Last 12 Months Of Insider Transactions At Consun Pharmaceutical Group
在康臣藥業集團過去12個月的內部交易中,有人進行了股票買賣。
The insider, Yubao An, made the biggest insider sale in the last 12 months. That single transaction was for HK$62m worth of shares at a price of HK$6.70 each. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The good news is that this large sale was at well above current price of HK$5.67. So it is hard to draw any strong conclusion from it.
在過去12個月的內部交易中,內部人員鞠葆進行了最大規模的內部人員賣出。 這單筆交易金額爲6200萬港元,每股售價爲6.70港元。儘管內部人員的賣出是一個負面因素,對我們來說,如果股票以更低價格出售,將更加負面。 好消息是,這筆大額銷售的價格遠高於目前的5.67港元。 因此,很難從中得出任何明確的結論。
Happily, we note that in the last year insiders paid HK$22m for 4.14m shares. But insiders sold 10.51m shares worth HK$70m. All up, insiders sold more shares in Consun Pharmaceutical Group than they bought, over the last year. The sellers received a price of around CN¥6.68, on average. We are not joyful about insider selling. But the selling was at much higher prices than the current share price (HK$5.67), so it probably doesn't tell us a lot about the value on offer today. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
令人高興的是,我們發現在過去一年內,內部人員支付了2200萬港元購買414萬股股票。 但內部人員賣出了價值7000萬港元的1051萬股。 總的來說,內部人員在康臣藥業集團賣出的股票數量多於購買的數量。 賣家平均得到了約6.68人民幣的價格。 我們對內部人員的賣出行爲並不感到高興。 但這些賣出行爲的價格遠高於當前股價(5.67港元),因此可能並不能反映出當下的價值。 下圖顯示了過去一年內部交易(公司和個人)的情況。 如果您單擊圖表,您可以查看所有的個人交易,包括股價、個人和日期!
If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.
如果您和我一樣,您就不會錯過這個免費的小盤股票列表,這些股票不僅被內部人士購買,而且估值也很有吸引力。
Does Consun Pharmaceutical Group Boast High Insider Ownership?
康濟藥業集團是否擁有高比例內部持股?
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. Consun Pharmaceutical Group insiders own 45% of the company, currently worth about HK$2.1b based on the recent share price. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
另一種測試公司領導人和其他股東之間對齊程度的方法是查看他們擁有多少股份。如果內部人員擁有大量股份,我認爲這是一個好跡象。康濟藥業集團內部人員擁有公司45%的股份,根據最近的股價,目前價值約21億港元。我很喜歡看到這種程度的內部持股,因爲它增加了管理層考慮股東最佳利益的可能性。
So What Does This Data Suggest About Consun Pharmaceutical Group Insiders?
那麼,這些數據對康濟藥業集團內部人員有何意義?
The recent insider purchases are heartening. On the other hand the transaction history, over the last year, isn't so positive. The recent buying by some insiders , along with high insider ownership, suggest that Consun Pharmaceutical Group insiders are fairly aligned, and optimistic. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Case in point: We've spotted 2 warning signs for Consun Pharmaceutical Group you should be aware of.
最近的內部購買是令人鼓舞的。另一方面,過去一年的交易歷史並不樂觀。一些內部人員最近的購買行爲,以及高比例內部持股,表明康濟藥業集團內部人員的利益基本一致,並且持樂觀態度。因此,了解內部人員在買賣方面的行爲對於了解一家特定公司面臨的風險也是有幫助的。具體例子:我們發現了康濟藥業集團存在兩個警示信號,您應該注意。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
當然,您可能會在其他地方找到一項出色的投資。因此,請查看此免費的有趣公司列表。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。